In a randomized, double-blind, placebo-controlled, dose-finding trial, siRNA against apo(a) (olpasiran, 10-mg doses for different time intervals) significantly decreased Lp(a) levels in patients with established ASCVD who had an Lp(a) concentration >150 nmol/L [101••]. Here, LPA is linked to atherosclerosis.